» Articles » PMID: 35880386

The Evolution of Immune Dysfunction in Multiple Myeloma

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2022 Jul 26
PMID 35880386
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This review discusses the role of immune dysfunction at the different stages of multiple myeloma (MM).

Methods: Narrative review.

Results: MM is a complex disease and immune dysfunction has been known to play an important role in disease pathogenesis, progression, and drug resistance. MM is known to be preceded by asymptomatic precursor states and progression from the precursor states to MM is likely related to a progressive impairment of the immune system.

Conclusions: An understanding of the role of the immune system in the progression of MM is important to guide the development of immunotherapeutic strategies for this disease.

Citing Articles

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen.

Zhang Q, Wang Y, Shi W, Chen Y, He Z, Yu L Sci Rep. 2025; 15(1):1819.

PMID: 39805912 PMC: 11731002. DOI: 10.1038/s41598-024-84343-x.


Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: a novel risk model construction.

Min R, Hu Z, Zhou Y Clin Exp Med. 2024; 24(1):249.

PMID: 39470826 PMC: 11522179. DOI: 10.1007/s10238-024-01499-6.


Bispecific Antibodies in Hematological Malignancies: A Scoping Review.

Omer M, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M Cancers (Basel). 2023; 15(18).

PMID: 37760519 PMC: 10526328. DOI: 10.3390/cancers15184550.